GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 5_Supplement ( 2023-03-01), p. P1-02-04-P1-02-04
    Abstract: Background The Regan Composite Risk Score (RCRS) is a web-based prognostic and predictive calculator to guide the use of adjuvant exemestane plus ovarian function suppression (AI + OFS) versus tamoxifen plus ovarian function suppression (TAM + OFS) or tamoxifen alone (TAM) for premenopausal women with hormone receptor-positive HER2-negative early breast cancer (HR+/HER2- EBC). We compared our adjuvant endocrine therapy policy based on the tumor board with the treatment guided by the RCRS during 2 time periods, one before and one after the acquaintance of the Tamoxifen and Exemestane Trial (TEXT) and Suppression and Ovarian Function Trial (SOFT) data. This allowed us to see a possible evolution in therapy policy. Methods A retrospective cohort study of 563 premenopausal patients with HR+/HER2- and HER2+ EBC diagnosed at the University Hospital of Leuven during 2 periods, 2010-2012 (cohort 1) and 2015-2017 (cohort 2), was conducted. For each patient with HER2- EBC, the RCRS was calculated by entering the requested characteristics in the online available tool. The primary outcome was to investigate how frequent our therapy differed from the therapy guided by the RCRS based on the estimated 8-yr distant relapse free interval (DRFI) with an arbitrary cut-off set at 3 %. If the received therapy was ≥ 3 % less efficient in 8-year DRFI compared to the optimal therapy according to RCRS, the patient was considered undertreated. If the received therapy differed by less than 3 % in 8-year DRFI compared to the optimal therapy according to RCRS and yet the most intensive therapy (AI + OFS & gt; TAM + OFS & gt; TAM) was administered, the patient was considered overtreated. In the other cases, the patient was considered to have been treated concordant with the RCRS. Secondarily, nonadherence of the HER2- and HER2+ patients towards the endocrine treatments leading to therapy switch because of intolerance was recorded at 6, 12, 24 and 36 months. Analyses were performed using SAS software and the comparison of both cohorts was performed by the chi-squared test for categorical variables. Results According to the RCRS, 43.2 % (89/206) of the HER2-negative patients of cohort 1 were undertreated compared to 22.1 % (43/194) in cohort 2 (chi- squared test, p-value & lt; 0.001). The number of overtreated patients also differed significantly between the two cohorts (chi-squared test, p-value = 0.003) with 2.9 % (6/206) in the first cohort and 10.3 % (20/194) in the second cohort. Finally, the number of patients treated concordant with the guidance derived from the RCRS was 53.9 % (111/206) in cohort 1 and 67.5 % (131/194) in cohort 2 (chi-squared test, p-value = 0.005). Treatment intolerance and switch was observed in 34.8 %, 16.7 % and 12.4 % of the patients receiving AI + OFS, TAM + OFS or TAM as initial therapy respectively; this was numerically higher for all treatments in cohort 2 vs cohort 1, although the observed difference was only significant for TAM. Conclusion In our center, a recent cohort of premenopausal women was more likely to be treated with the adjuvant endocrine treatment concordant with the guidance derived from the RCRS when using an arbitrary cut-off of 3 % to define a relevant improvement in outcome. Citation Format: Charlotte Berteloot, Patrick Neven, Maja Vangoitsenhoven, Annouschka Laenen, Hans Wildiers, Kevin Punie, Ann Smeets, Ines Nevelsteen, Sileny Han, Thaïs Baert, Hilde Janssen, Eva Oldenburger, Adinda Baten, Patrick Berteloot, Rani Vanhoudt, Anne Deblander, Chantal Remmeriev, Christine Desmedt. Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-02-04.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Acta Clinica Belgica, Informa UK Limited, Vol. 73, No. 2 ( 2018-03-04), p. 100-109
    Type of Medium: Online Resource
    ISSN: 1784-3286 , 2295-3337
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2018
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 176, No. 3 ( 2019-8), p. 699-708
    Type of Medium: Online Resource
    ISSN: 0167-6806 , 1573-7217
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 2004077-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 115, No. 2 ( 2009-5), p. 349-358
    Type of Medium: Online Resource
    ISSN: 0167-6806 , 1573-7217
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2009
    detail.hit.zdb_id: 2004077-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Menopause, Ovid Technologies (Wolters Kluwer Health), Vol. 18, No. 2 ( 2011-02), p. 224-229
    Type of Medium: Online Resource
    ISSN: 1072-3714
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2011
    detail.hit.zdb_id: 2071114-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 4_Supplement ( 2021-02-15), p. PS7-63-PS7-63
    Abstract: Introduction Accurate information on cause of death is essential for correct breast cancer-specific mortality assessment. However, registration and coding of cause of death is prone to error since determining the exact underlying condition related to the death is challenging. In this study, an expert review of medical files was done to determine the principal cause of death for breast cancer patients of a Belgian tertiary hospital. The retrieved cause of death was compared to death certificate information to assess concordance between both sources. Secondly, the impact of discordant reporting on cause-specific survival (CSS) and other net survival approaches were examined. Methods Breast cancer patients diagnosed and treated at University Hospitals Leuven (UHL) between 2009 and 2014 with follow-up until December 31st, 2016, were included in the study. Information on cause of death was obtained from death certificates (following ICD-10 rules) and medical files. The latter were reviewed by a board of experts at UHL. Agreement was calculated using Cohen’s kappa coefficient, and reasons for discordant reporting were assessed. CSS was calculated based on cause of death information from both sources using the Kaplan-Meier method. These survival estimates were compared to the relative survival probability (RS) using the Ederer II and Pohar Perme method. Results A total of 2,862 patients were included, of whom 354 died after a median follow-up of 54.6 months. We found overall substantial agreement (kappa-value of 0.69 (95% C.I.: 0.62-0.77)) between cause of death reported by death certificates and medical files (Table 1). In 84.8% of cases, there was concordance between both methods. When comparing to medical files, misattribution of breast cancer-specific death in death certificates (4.5% of cases) was linked to the presence of comorbidities (43.7%), metastases (37.5%), or unspecified causes (18.8%). Five-year CSS based on medical files (93.1% (95% C.I.: 91.9-94.1)) was only slightly higher compared to CSS based on death certificates (92.3% (95% C.I.: 91.2-93.4)). RS measures using Ederer II and Pohar Perme were comparable to CSS measures. Conclusions Overall, substantial agreement of cause of death was seen between death certificates and medical files. Attribution of cause death to comorbidities was the most common reason for discordant reporting of breast cancer-specific death. Five-year breast cancer-specific survival was slightly higher based on cause of death information from medical files, compared to death certificates. Periodic reviews and implementation of ICD-10 guidelines for classification of cause of death could improve accuracy in cause of death annotation. Table 1: Discordance for the principal cause of death between medical files and death certificatesmedical filesother causesbreast cancerdeath certificatesother causes136 (38.4%)16 (4.5%)152 (42.9%)breast cancer38 (10.7%)164 (46.3%)202 (57.1%)174 (49.2%)180 (50.9%)354 (100%) Citation Format: Hava Izci, Tim Tambuyzer, Jessica Vandeven, Jérôme Xicluna, Hans Wildiers, Kevin Punie, Nynke Willers, Eva Oldenburger, Els Van Nieuwenhuysen, Patrick Berteloot, Ann Smeets, Ines Nevelsteen, Liesbet Van Eycken, Harlinde De Schutter, Patrick Neven, Geert Silversmit, Freija Verdoodt. Cause of death discordance between death certificates and medical files: Impact on cancer survival assessment in a Belgian case study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-63.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P2-14-23-P2-14-23
    Abstract: Introduction Based on immunohistochemistry, triple-negative breast cancer (TNBC) lacks ER, PR and HER2, rendering them non-eligible for hormone or HER2 targeted therapy. Adjuvant chemotherapy (aCT) is often not initiated based on clinical decision making (low risk of relapse, comorbidities, older age), but sometimes because of patient refusal. We aimed to compare clinical-pathologic characteristics and outcome of patients with TNBC by reason to abstain from aCT (based on a clinical decision or patient refusal) with patients who did receive aCT. Methods In this retrospective study, we consecutively included patients with primary operable TNBC who received primary surgery, diagnosed and treated at University Hospitals Leuven between 2000-2017 (median follow-up of 9 years). The underlying reason for patients who did not receive aCT was obtained by performing a chart review: (1) by clinical decision for various different reasons: e.g. low risk of relapse (special histological subtypes e.g. adenoid cystic carcinoma, small pN0 lesions), comorbidities, older age or (2) by patient refusal. Distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS) were studied endpoints. Cox proportional hazard regression models were used to estimate hazard ratios (HR) and 95% confidence intervals. All statistical tests are two-sided, a 5% significance level was assumed for all tests. Analyses have been performed using SAS software (version 9.4 of the SAS System for Windows). Results We included 673 patients with TNBC of whom 163 (24.2%) did not receive aCT; 141 (20.9%) due to a clinical decision, and 22 (3.3%) due to patient refusal. Mean age at diagnosis was 71.6 years and 68.7 years, respectively, compared to 52.3 years for those who received aCT. Patients who received aCT showed a tendency towards better DDFS when compared to the group of patients who refused aCT (HR=0.621 [0.217;1.774]; p=0.37), and when compared to the group who did not receive aCT due to a clinical decision (HR=0.545 [0.294;1.009] ; p=0.05). The group of patients who did not receive aCT due to a clinical decision showed a tendency towards worse DDFS compared to the group of patients who refused aCT (HR=1.140 [0.390;3.30]; p=0.81), however this difference was not statistically significant. Interestingly, BCSS for patients who received aCT was better compared to patients who did not receive aCT due to a clinical decision (HR=0.484 [0.250;0.935] ; p=0.03) and showed a tendency towards better survival when compared to the group of patients who refused aCT (HR= 0.582 [0.174;1.946]; p=0.38). Patients who did not receive aCT due to a clinical decision showed a tendency towards worse BCSS than patients refusing therapy (HR=1.204 [0.353;4.089] ; p=0.77). Conclusion In this cohort, TNBC patients treated with primary surgery who refused aCT appeared to have worse DDFS and BCSS compared to patients who received aCT. Patients who did not receive aCT due to a clinical decision hade worse BCSS and a tendency towards worse DDFS, compared to patients who received aCT. These results suggest that chemotherapy is effective in reducing cancer-related mortality. Citation Format: Hava Izci, Jan Ardui, Annouschka Laenen, Freija Verdoodt, Giuseppe Floris, Laurence Slembrouck, Ignace Vergote, Ann Smeets, Els Van Nieuwenhuysen, Sileny Han, Ines Nevelsteen, Caroline Weltens, Patrick Berteloot, Kevin Punie, Hans Wildiers, Patrick Neven. Outcome of patients with triple-negative breast cancer who did not receive adjuvant chemotherapy [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-14-23.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P1-10-04-P1-10-04
    Abstract: Background. High levels of sTIL have been associated with an increased pCR rate after NACT. Recent experimental and human data have demonstrated that obesity is associated with T-cell dysfunction (mediated by increased expression of checkpoints PD-1, LAG3 and TIM3), herewith reducing antitumor immune response. Here, we evaluated the value of sTIL in predicting pCR and prognosis in TNBC treated with NACT according to patient’s BMI. Patients and methods. We considered two institutional retrospective series of 452 TNBC patients treated with NACT (Leuven: n= 174, and, Curie: n= 278). Underweight patients ( & lt;18.5 kg/m2) were excluded (n=6). TNBC was defined by ER ( & lt;1%), PR & lt;1% and HER2 negativity. sTIL were scored centrally by an experienced pathologist (GF) on pre-treatment biopsies according to standard guidelines (Salgado Annals of Oncol 2015). In agreement with recent TNBC literature, highly infiltrated tumors were defined as ≥ 30% TIL (Loi J Clin Oncol 2019). BMI was binarized for the main analyses (lean (18.5-25 kg/m2) versus overweight & obese (≥25 kg/m2)). Associations between BMI and clinico-pathological variables were assessed using the Fisher exact test, associations with pCR (ypT0/is N0) using conditional logistic regression, and associations with disease-free (DFS) and overall survival (OS) using Cox proportional hazard regressions. Menopausal status, grade and stage were considered as adjustment variables, and center as stratification factor. An interaction term was considered between TIL and BMI. P-values were considered as significant when & lt;.05. Results. 236 (53%), 132 (30%) and 77 (17%) patients were lean, overweight and obese, respectively. pCR was achieved in 181/445 (41%) of the patients. Median sTIL was 11% and 99/445 (22%) tumors had high sTIL. Median follow-up time was 7.63 years. BMI was associated with menopausal status (33.8% lean and 50.4% overweight & obese patients were postmenopausal, p & lt;.001), stage (30.5% lean and 41.1% overweight & obese patients were stage 2/3, p=.022), and histological grade (85.8% lean and 91.8% overweight & obese patients had grade 2/3 tumors, p=.051). BMI was not associated with sTIL (p=.910). Regression analyses revealed a statistically significant interaction between sTIL and BMI for predicting pCR both in the unadjusted (p=.024) and adjusted analysis (p=.033) (see alsoTable 1). sTIL were significantly associated with pCR in lean (ORadj: 4.24, 2.10-8.56, p & lt;.001), but not in overweight and obese patients (ORadj: 1.48, 0.75-2.91, p=.257). Exploratory analyses using the 3 BMI categories were consistent with previous results (lean ORadj: 4.24, 2.10-8.57, p & lt;.001, overweight ORadj: 1.45, 0.64-3.24, p=.372, obese ORadj: 1.51, 0.42-5.40, p=.523). Survival analyses revealed a statistically significant association of sTIL with DFS with higher sTIL being associated with better DFS in lean patients (hazard ratio, HRadj: 0.29, 0.12-0.67, p & lt;.001), but not in overweight & obese patients (HRadj: 1.72, 0.90-3.31, p=.101). The interaction term did however not reach statistical significance. Similar results were obtained for OS. Conclusion. In this study, we demonstrated that in TNBC patients treated with NACT, high sTIL predict pCR and favorable prognosis only in lean patients. Table 1. Unadjusted and adjusted associations with pCR in TNBC.Unadjusted OR, 95% CIAdjusted OR (95% CI)sTIL (≥30 vs & lt;30%)2.71 (1.71-4.28), p & lt;.0014.24 (2.10-8.56), p & lt;.001BMI (≥25 vs & lt;25 kg/m2)0.71 (0.48-1.04], p=.0750.87 (0.55-1.39), p=.572Menopausal status (post vs pre)0.73 (0.49-1.07), p=.1070.83 (0.54-1.26), p=.373Stage (2+3 vs 1)0.63 (0.41-0.98), p=.0390.59 (0.37-0.94), p=.026Grade (2+3 vs 1)2.42 (1.23-4.78), p=.0112.20 (1.09-4.47), p=.029 Citation Format: Christine Desmedt, François Richard, Lynn Jongen, Anne-Sophie Hamy-Petit, Hans Wildiers, Jan Ardui, Kevin Punie, Ann Smeets, Patrick Berteloot, Ignace Vergote, Maricl Lae, Diane Decroze, Didier Meseure, Fabien Reyal, Elia Biganzoli, Patrick Neven, Giuseppe Floris. Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-10-04.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P5-06-08-P5-06-08
    Abstract: Purpose: Extended adjuvant hormone therapy improves estrogen receptor (ER)-positive breast cancer outcome. The total duration of endocrine therapy is still a subject for debate. The CTS5 score, developed by Dowsett et al1., predicts late distant recurrence (LDR) between years 5 and 10 after diagnosis in ER-positive invasive breast cancers in postmenopausal women. This LDR risk might be used to select patients for extended endocrine therapy. The CTS5 score is calculated using age at the start of endocrine therapy, tumor size, grade, and lymph node status. The aim of this study is the validation of this tool in a series of women from the UZ Leuven. Methods: This retrospective cohort study included 1125 postmenopausal women consecutively diagnosed with invasive estrogen receptor (ER) positive breast cancer who stopped endocrine therapy after 4.5 to 5.5 years. Tissue was tested for ER positivity and considered positive if & gt;1% of tumor nuclei were stained. HER2 status was defined according to ASCO guidelines. Statistical analysis was performed by Cox proportional hazards models which determined the prognostic performance of the CTS5 score for LDR. Results: A total of 1125 patients were included in this analysis, of which 1097 had a known HER2 status and 1023 were negative. 62 of 1125 (5.5%) developed an LDR between years 5 and 10. The continuous CTS5 was a significant predictor for LDR (HR =2.69 (1.99-3.60), p & lt;0.001). The tool was not significant in the HER2 positive population (n=74), but numbers were small with only 5 LDR recorded (HR=0.92 (0.32-2.66), p=0.88). Further analysis was performed in a strictly HER2-negative cohort. In this cohort, 8 of the 401 patients (2.0%) with a CTS5 predicted low risk ( & lt;5% LDR risk) developed LDR, in the intermediate risk group (5-10% LDR risk) 16 out of 336 (4.8%) and in the high risk group (≥10% LDR risk) 32 out of 286 (11.2%) developed LDR. Conclusion: In our series of postmenopausal women, CTS5 accurately predicts late distant recurrence in ER-positive, HER2-negative early invasive breast cancers. The CTS5-score, identifying a patient group with LDR risk of ≥5%, might be used to discuss the benefits of extended endocrine therapy for individual patients. However, the exact predictive value for the benefit of prolonged therapy can only be based on a randomized controlled trial (RCT) using the LDR risk as a stratification factor. It would be of great value to expand the study population, especially HER2-positive tumors, and define the prognostic performance of the CTS5 score in premenopausal women. Further research is needed. 1. Dowsett, M. et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J. Clin. Oncol. 36, 1941-1948 (2018). Citation Format: Josephine Van Cauwenberge, Ivana Sestak, Kevin Punie, Hans Wildiers, Giuseppe Floris, Ignace Vergote, Patrick Berteloot, Toon Van Gorp, Ann Smeets, Els Van Nieuwenhuysen, Sileny Han, Ines Nevelsteen, Caroline Weltens, Hilde Janssen, Patrick Neven. Predicting distant recurrence of ER+ HER2- breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-06-08.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P3-08-26-P3-08-26
    Abstract: Purpose: Metaplastic Breast Cancer (mBC) is uncommon and often behaves aggressive with a high incidence of recurrence. Prognostic factors are poorly understood. We analyzed prognostic factors in a single center series of triple negative mBC and compared those to a patients with ductal TNBC of no special type (dTNBC-NST), treated during the same time period; Materials and methods: We retrospectively analyzed prognostic factors (demographic and clinical pathological features) and distant recurrence of all ER-negative mBC’s (primary operated and neoadjuvant chemotherapy (NAC-)) treated in the University Hospitals Leuven (UHL) between 1/1/2000 and 31/12/2016. TNBC was defined as IHC-ER & lt;1%, IHC-PR & lt;1% and IHC-HER2 0-1+ and FISH negative if HER2 IHC 2/3+. For comparison, only ductal TNBC of no special type were included (dTNBC-NST). Demographic features included age, Body Mass Index (BMI, kg/m²) and detection method. Clinical pathological features included grading, size, lymphovascular invasion (LVI) and nodal involvement. Outcome included distant recurrence rate. The Cox proportional hazards model was used to analyze prognostic factors on distant recurrence rate. A multivariate model was used to correct for possible confounders (grade, nodal stage, tumor size). The clinical pathological variables were compared using Fisher exact test or Mann-Withney U test. All tests are two-sided and a 5% significance level is assumed for all tests. Results on distant recurrent rates are presented as hazard ratios (HR) with 95% confidence intervals (CI). Results: 49 mBC patients were identified; 11 treated with NAC and 38 primary operated. The dTNBC-NST group contained 662 patients; 194 treated with NAC and 468 primary operated. Median follow up was 8.35yrs [5.33 - 12.16] in the mBC and 9.48yrs [5.23-13.44] in the dTNBC-NST group. Median age was 52yr in the mBC and 53yr in the dTNBC-NST (p=0.482). There was a tendency for a higher BMI in the mBC group: median BMI was 26.4kg/m² in mBC and 24.7kg/m² in the dTNBC-NST group (p=0.09, univariate analysis). Tumors were significantly larger in the mBC group with the median size (mm) of 29.5 in mBC and 25.0 in dTNBC-NST (p=0.008). Nodal involvement was 17/49 (34.7%) in the mBC group and 205/662 (31.0%) in dTNBC-NST (p=0.345). LVI was significantly less present in mBC (7.9%) than in dTNBC-NST (24.4%) (p=0.026). A similar proportion in either group received adjuvant chemotherapy (76.3% in mBC and 80.8% in dTNBC-NST) but mBC received more often adjuvant radiotherapy (85.7% in mBC and 60.1% in dTNBC-NST, p & lt;0.01) despite having a similar mastectomy rate (51.0% in mBC and 47.6% in dTNBC-NST, p=0.659). pCR in NAC treated mBC was achieved in 4/11 (36.4%) and in 86/194 (43.9%) of dTNBC-NST (p=0.785). There is a tendency to a higher distant relapse rate in mBC with 28.9% (95% CI: 16.5;42.5) having distant relapse within 5 years compared to 16.6% (95% CI: 13.8;19.7) in dTNBC-NST) [HR 1.722, 95% CI (0.970 - 3.057), p=0.064)]. However, when corrected in a multivariate model (corrected for grade, nodal stage and size) this trend becomes irrelevant [HR 1.189, 95% CI (0.659 - 2.144)] . Conclusion: mBC is larger at diagnosis and less often LVI-pos compared to dTNBC-NST. Adjuvant radiotherapy was more often given to mBC patients. The trend we observed of more distant relapse in mBC disappeared when corrected for tumor characteristics. Citation Format: Jan Ardui, Kevin Punie, Giuseppe Floris, Hava Izci, Hans Wildiers, Ignace Vergote, Patrick Berteloot, Toon Van Gorp, Annouschka Laenen, Ann Smeets, Caroline Weltens, Patrick Neven. Clinico-pathological characteristics of metaplastic breast cancer as compared to normal TNBC: A single center analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-08-26.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...